Do analysts prefer PLUR or CYPH?

Cypherpunk Technologies has a consensus target price of $0.90, indicating a potential upside of 39.75%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Cypherpunk Technologies is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts recommend GANX or PLUR?

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GANX or PLUR more profitable?

Gain Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Pluri -2,162.08% N/A -106.59%

Do analysts rate PLUR or IBIO?

iBio has a consensus price target of $5.00, suggesting a potential upside of 249.65%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Which has stronger valuation and earnings, PLUR or IBIO?

iBio has lower revenue, but higher earnings than Pluri. iBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 12.78 -$22.58M -$4.53 N/A iBio $400K 177.61 -$18.38M -$0.58 N/A

Is PLUR or IBIO more profitable?

iBio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% iBio N/A -53.86% -46.48%

Do analysts recommend ALPS or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALPS or PLUR more profitable?

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Company Net Margins Return on Equity Return on Assets ALPS Group Inc Ordinary Share N/A N/A N/A Pluri -2,162.08% N/A -106.59%

Do analysts prefer PLUR or ACRV?

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 592.31%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Pluri (PLUR) Competitors

$1.59 -0.07 (-4.48%)

Closing price 03:58 PM Eastern

Extended Trading

$1.62 +0.03 (+1.76%)

As of 04:38 PM Eastern

Compare

PLUR vs. CYPH, GANX, IBIO, ALPS, and ACRV

Should you buy Pluri stock or one of its competitors? Pluri's main competitors and comparable companies include Cypherpunk Technologies (CYPH), Gain Therapeutics (GANX), iBio (IBIO), ALPS Group Inc Ordinary Share (ALPS), and Acrivon Therapeutics (ACRV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pluri compare to Cypherpunk Technologies?

Pluri (NASDAQ:PLUR) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Cypherpunk Technologies has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Pluri has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

16.6% of Pluri shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cypherpunk Technologies has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	1.15

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Pluri. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Cypherpunk Technologies' score of 0.55 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Cypherpunk Technologies	Positive

Cypherpunk Technologies has a consensus target price of $0.90, indicating a potential upside of 39.75%. Given Cypherpunk Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Cypherpunk Technologies is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Cypherpunk Technologies beats Pluri on 10 of the 15 factors compared between the two stocks.

How does Pluri compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 253.77%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gain Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Pluri	-2,162.08%	N/A	-106.59%

Gain Therapeutics has higher earnings, but lower revenue than Pluri. Gain Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A

In the previous week, Gain Therapeutics had 8 more articles in the media than Pluri. MarketBeat recorded 9 mentions for Gain Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Gain Therapeutics' score of 1.01 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Pluri	Very Positive

Summary

Gain Therapeutics and Pluri tied by winning 8 of the 16 factors compared between the two stocks.

How does Pluri compare to iBio?

Pluri (NASDAQ:PLUR) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, iBio had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for iBio and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat iBio's score of 1.45 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
iBio	Positive

iBio has lower revenue, but higher earnings than Pluri. iBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A
iBio	$400K	177.61	-$18.38M	-$0.58	N/A

iBio has a consensus price target of $5.00, suggesting a potential upside of 249.65%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

16.6% of Pluri shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, iBio has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

iBio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
iBio	N/A	-53.86%	-46.48%

Summary

iBio beats Pluri on 11 of the 17 factors compared between the two stocks.

How does Pluri compare to ALPS Group Inc Ordinary Share?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

ALPS Group Inc Ordinary Share has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALPS Group Inc Ordinary Share	$4.86M	10.96	-$980K	$0.33	0.97
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%.

Company	Net Margins	Return on Equity	Return on Assets
ALPS Group Inc Ordinary Share	N/A	N/A	N/A
Pluri	-2,162.08%	N/A	-106.59%

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 25.5% of ALPS Group Inc Ordinary Share shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ALPS Group Inc Ordinary Share had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for ALPS Group Inc Ordinary Share and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat ALPS Group Inc Ordinary Share's score of 1.45 indicating that Pluri is being referred to more favorably in the news media.

Company	Overall Sentiment
ALPS Group Inc Ordinary Share	Positive
Pluri	Very Positive

ALPS Group Inc Ordinary Share has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Pluri has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ALPS Group Inc Ordinary Share beats Pluri on 8 of the 12 factors compared between the two stocks.

How does Pluri compare to Acrivon Therapeutics?

Pluri (NASDAQ:PLUR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Pluri has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Pluri has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

16.6% of Pluri shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acrivon Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Pluri. MarketBeat recorded 7 mentions for Acrivon Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Acrivon Therapeutics' score of 1.01 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Acrivon Therapeutics	Positive

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 592.31%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Acrivon Therapeutics beats Pluri on 9 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.93M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.35	10.67	269.06	25.28
Price / Sales	12.78	1,262.99	592.57	87.62
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-14.43	16.78	12.91	6.24
Net Income	-$22.58M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-13.75%	1.74%	1.12%	1.07%
1 Month Performance	-5.54%	1.60%	1.79%	1.03%
1 Year Performance	-68.35%	56.43%	67.69%	20.77%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	1.0714 of 5 stars	$1.59 -4.5%	N/A	-65.4%	$17.93M	$1.34M	N/A	150	Analyst Upgrade Gap Up
CYPH Cypherpunk Technologies	3.3169 of 5 stars	$0.71 +2.8%	$0.90 +26.9%	+91.2%	$75.48M	N/A	N/A	40	Earnings Report
GANX Gain Therapeutics	2.8247 of 5 stars	$1.77 +0.3%	$7.50 +324.9%	+39.4%	$75.11M	$50K	N/A	20	Positive News Earnings Report Analyst Forecast
IBIO iBio	3.4597 of 5 stars	$1.41 -3.8%	$5.00 +255.9%	N/A	$69.80M	$300K	N/A	100	Positive News
ALPS ALPS Group Inc Ordinary Share	1.6896 of 5 stars	$0.41 +4.4%	N/A	N/A	$68.89M	N/A	1.25	N/A	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors

PLUR vs. CYPH, GANX, IBIO, ALPS, and ACRV

How does Pluri compare to Cypherpunk Technologies?

Summary

How does Pluri compare to Gain Therapeutics?

Summary

How does Pluri compare to iBio?

Summary

How does Pluri compare to ALPS Group Inc Ordinary Share?

Summary

How does Pluri compare to Acrivon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pluri (PLUR) Competitors

PLUR vs. CYPH, GANX, IBIO, ALPS, and ACRV

How does Pluri compare to Cypherpunk Technologies?

Is PLUR or CYPH more profitable?

Which has more volatility and risk, PLUR or CYPH?

Do insiders & institutionals believe in PLUR or CYPH?

Which has better earnings & valuation, PLUR or CYPH?

Does the media prefer PLUR or CYPH?

Do analysts prefer PLUR or CYPH?

Summary

How does Pluri compare to Gain Therapeutics?

Which has more risk & volatility, GANX or PLUR?

Do insiders & institutionals believe in GANX or PLUR?

Do analysts recommend GANX or PLUR?

Is GANX or PLUR more profitable?

Which has higher valuation and earnings, GANX or PLUR?

Does the media favor GANX or PLUR?

Summary

How does Pluri compare to iBio?

Does the media refer more to PLUR or IBIO?

Which has stronger valuation and earnings, PLUR or IBIO?

Do analysts rate PLUR or IBIO?

Do insiders & institutionals have more ownership in PLUR or IBIO?

Which has more risk & volatility, PLUR or IBIO?

Is PLUR or IBIO more profitable?

Summary

How does Pluri compare to ALPS Group Inc Ordinary Share?

Which has better valuation & earnings, ALPS or PLUR?

Is ALPS or PLUR more profitable?

Do institutionals & insiders believe in ALPS or PLUR?

Does the media favor ALPS or PLUR?

Which has more risk & volatility, ALPS or PLUR?

Do analysts recommend ALPS or PLUR?

Summary

How does Pluri compare to Acrivon Therapeutics?

Which has preferable valuation and earnings, PLUR or ACRV?

Which has more volatility and risk, PLUR or ACRV?

Do insiders and institutionals hold more shares of PLUR or ACRV?

Is PLUR or ACRV more profitable?

Does the media refer more to PLUR or ACRV?

Do analysts prefer PLUR or ACRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools